Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MST1R | Q04912 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587157 | 0.88 | MET (0.73) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL16587092 | 0.88 | MET (0.73) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL12689735 | 0.85 | MET (0.78) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL13452995 | 0.81 | MET (0.52) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL16587175 | 0.80 | MET (0.57) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL16587148 | 0.80 | MET (0.79) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL16587133 | 0.80 | MET (0.79) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL16587143 | 0.80 | MET (0.59) | METPDE3BPDE3A | |
| SCHEMBL12489197 | 0.76 | MET (0.73) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL22109153 | 0.75 | MET (0.72) | METNQO2PDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956218-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2018-05-01 | — | — | US | disclosed |
| US-20170027934-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-02-02 | — | — | US | disclosed |
| US-8987269-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027934-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | MET 4578/4885NQO2 627/4885PDE4C 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.